What is Lake Street Capital’s Forecast for CLPT Q3 Earnings?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Investment analysts at Lake Street Capital issued their Q3 2026 earnings per share (EPS) estimates for ClearPoint Neuro in a research note issued on Tuesday, October 20th. Lake Street Capital analyst F. Takkinen forecasts that the company will post earnings per share of ($0.36) for the quarter. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($1.22) per share.

A number of other analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Thursday, October 15th. Wall Street Zen cut ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Stifel Nicolaus set a $22.00 target price on ClearPoint Neuro in a research note on Tuesday, August 4th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $25.67.

ClearPoint Neuro Price Performance

CLPT stock opened at $9.25 on Thursday. ClearPoint Neuro has a 12 month low of $8.27 and a 12 month high of $27.27. The company has a current ratio of 4.74, a quick ratio of 3.89 and a debt-to-equity ratio of 4.66. The company has a 50-day moving average price of $13.26 and a 200 day moving average price of $13.51. The stock has a market cap of $282.12 million, a PE ratio of -7.84 and a beta of 1.29.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.09). ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%. The firm had revenue of $10.88 million for the quarter, compared to analysts’ expectations of $12.73 million. During the same period in the previous year, the firm earned ($0.21) earnings per share.

Institutional Investors Weigh In On ClearPoint Neuro

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in ClearPoint Neuro in the 2nd quarter worth about $42,456,000. SG Americas Securities LLC bought a new stake in shares of ClearPoint Neuro during the first quarter valued at approximately $3,388,000. Compass Financial Management LLC bought a new stake in shares of ClearPoint Neuro during the second quarter valued at approximately $5,275,000. Bank of New York Mellon Corp purchased a new stake in shares of ClearPoint Neuro in the second quarter valued at approximately $2,708,000. Finally, FirstWave Capital Management LLC boosted its holdings in shares of ClearPoint Neuro by 20.6% in the second quarter. FirstWave Capital Management LLC now owns 115,600 shares of the company’s stock valued at $2,062,000 after purchasing an additional 19,760 shares during the period. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes image-guided systems for minimally invasive neurosurgical procedures. Its platform is designed to help physicians plan, navigate and monitor procedures within the brain, using magnetic resonance imaging (MRI) to support accurate placement of instruments and therapeutic agents.

The company’s product portfolio includes the ClearPoint Neuro navigation system and related disposable components, including cranial access and guidance products.